Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.62 |
| ▸ | NPC1 | O15118 | 13/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.58 |
| ▸ | RELA | Q04206 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909456 | 0.88 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL13993370 | 0.85 | TRPV1 (0.48) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL30926503 | 0.83 | RAB9A (0.85) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL27181112 | 0.83 | RAB9A (0.85) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL5174929 | 0.82 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL5909198 | 0.81 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2PKMNFKB1 | |
| SCHEMBL13757202 | 0.81 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL13757257 | 0.79 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL21780052 | 0.78 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 | |
| SCHEMBL5174946 | 0.77 | RAB9A (0.75) | RAB9ANPC1SMN1; SMN2NPSR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | RAB9A 2274/4885NPC1 959/4885SMN1; SMN2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.